ABVC BioPharma

The business lacks recurring revenue and has high binary risk tied to clinical and regulatory outcomes. FY2025 revenue was zero and prior Q3 2025 revenue was restated to zero, indicating volatility and weak revenue recognition quality.

The pipeline is in Phase II for key assets (ABV‑1504/1505; ABV‑1701 device), which leaves timelines and outcomes uncertain. Geographic dispersion of activities across the US, Taiwan, and projects touching China adds operational and regulatory friction.